_256_384.jpg)
News | February 26, 2021
Bayer delivers robust performance despite pandemic
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
